Polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) are classical myeloproliferative neoplasms (MPN), characterized by specific somatic mutations in JAK2, CALR or MPL genes. JAK2 46/1 and TERT rs2736100 polymorphisms are known to significantly predispose to MPN. This study aimed to establish the additional contribution of the recently described MECOM rs2201862, HBS1L-MYB rs9376092 and THRB-RARB rs4858647 polymorphisms to the occurrence of MPN. These three polymorphisms, along with JAK2 46/1 and TERT rs2736100 were genotyped in 939 MPN patients (454 with ET, 337 with PV and 148 with PMF) and 483 controls. MECOM rs2201862 associated significantly with each MPN entity, except for ET, and with all major molecular sub-types, especially those CALR-mutated (OR 5 1.4; 95% CI 5 1.1-1.8; P-value 5 .005). HBS1L-MYB rs9376092 associated only with JAK2 V617F-mutated ET (OR 5 1.4; 95% CI 5 1.1-1.7; P-value 5 .003). THRB-RARB rs4858647 had a weak association with PMF only (OR 5 1.5; 95% CI 5 1-2.1; P-value 5 .04). Surprisingly, JAK2 46/1 haplotype was associated significantly not only with JAK2 V617F-mutated MPN, but also with CALR-mutated MPN (OR 5 1.4; 95% CI 5 1.1-1.8; P-value 5 .01). TERT rs2736100 was associated equally strong Adrian P. Trifa, Claudia B anescu, and Anca S. Bojan contributed equally to this work.
| I N TR ODU C TI ON
Polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) are the most frequent BCR-ABL-negative myeloproliferative neoplasms (MPN) , that are usually characterized by specific somatic driver mutations. Among these, JAK2 V617F is seen in almost all patients with PV and around half of patients with ET and PMF. Various CALR (calreticulin) indels are present in 25-30% of patients with ET and PMF, with a clear predominance of type 1 (a deletion of 52 bp) and 2 (an insertion of 5 bp) mutations. Finally, 3-10% of patients with ET and PMF harbor mutations at the MPL locus, which codes for the thrombopoetin receptor. JAK2, CALR, and MPL are mutually exclusive in most of the MPN patients. About 10-15% of patients with ET and PMF do not harbor any of these mutations, being called "triple-negative." Mutations in various other genes were added in the last years to this landscape, some of them having prognostic significance, especially in PMF. 1 Regarding the genetic predisposition to MPN, polymorphisms at JAK2 and TERT loci were shown unequivocally to strongly predispose to MPN. JAK2 46/1 haplotype predisposes especially to JAK2 V617F-mutated MPN, while rs2736100, located in the TERT (telomerase reverse transcriptase) gene, predisposes to all MPN, regardless of the clinical or molecular sub-type. [2] [3] [4] [5] We previously replicated these findings in our patients. 6, 7 Two genome wide association studies revealed recently additional variants influencing the risk of developing MPN, at various loci, such as MECOM, HBS1L1-MYB, THRB-RARB, SH2B3, TET2, CHEK2, ATM, PINT, and GFI1B. 8, 9 Among those variants, rs2201862, located downstream of MECOM gene, associated mainly with JAK2 V617F-negative MPN.
rs9376092, located between the HBS1L1 and MYB genes in the socalled HMIP region (HBS1L1-MYB intergenic region polymorphism), associated especially with CALR or MPL-positive MPN, and with JAK2 V617F-mutated ET. Another polymorphism, rs4858647, located between the THRB and RARB genes, shown a weaker association with MPN, more strongly with those JAK2 V617F-negative. 8 Here we aimed exploring the contribution of the recently described MECOM rs2201862, HBS1L1-MYB rs9376092, and THRB-RARB rs4858647, along with the well characterized JAK2 46/1 and TERT rs2736100 polymorphisms in defining the genetic predisposition to MPN, by analyzing a representative cohort of patients. We did not separate the pre-PMF and overt PMF patients, ascribing them to a single category, namely PMF. We considered only patients displaying one of the three driver mutations-JAK2 V617F, CALR or MPL. We were not able to include "triple-negative" patients, as in most of them a bone marrow examination was not performed and thus we were unaware of the true nature of their condition (reactive or clonal).
| M A TE RI A L A ND M E TH ODS

| Patients and controls
In the PV group the median age at diagnosis was 64 years (range 29-89 years) and there were 176 male patients (52.2%). All PV patients were JAK2 V617F-mutated.
In the ET group the median age at diagnosis was 59 years (range 17-91 years) and there were 167 male patients (37%). There were 320
patients JAK2 V617F-mutated (70.5%), 120 patients CALR-mutated (26.4%) and 14 MPL-mutated (3.1%). Among the CALR-mutated patients, 63 had type 1 mutation (52.5%), 15 had type 1-like mutations (12.5%), and 42 had type 2 mutation (35%). Among the MPL-mutated patients, 11 had W515L mutation, two had W515K mutation and one had S505N mutation.
In the PMF group the median age at diagnosis was 66 years (range 27-93 years). There were 93 patients JAK2 V617F-mutated (62.8%), 50 CALR-mutated (33.8%), and 5 MPL-mutated (3.4%). Among the CALR-mutated patients, 30 had type 1 mutation (60%), 4 had type 1-like mutations (8%), 14 had type 2 mutation (28%), and 2 had type 2-like mutations (4%). Among the MPL-mutated patients, 3 had W515L mutation and 2 had W515K mutation.
The study also included 483 individuals age-and gender-matched to the patients, serving as controls. They were enrolled to this study in parallel with the patients. These individuals were referred for blood workup at the Hematology Clinic from Cluj-Napoca, mainly due to various cytopenia (especially anemia) or cytosis (especially leukocytosis).
Only individuals in which cytopenia or cytosis proved to be not related to a hematological malignancy were finally included in the study.
The study was approved by the Ethics Committee of the Iuliu Haţieganu University of Medicine and Pharmacy, Cluj-Napoca. Written consent regarding the genetic testing was also obtained from each participant to the study.
| Genotyping experiments
All the experiments have been performed on genomic DNA obtained from peripheral blood withdrawn on EDTA. TERT rs2736100, MECOM rs2201862, HBS1L-MYB rs9376092, and THRB-RARB rs4858647 polymorphisms were genotyped in all patients and controls using TaqMan SNP Genotyping assays purchased from Applied Biosystems, according to manufacturer's instructions, and run on a QuantStudio 3 real-time PCR machine (Applied Biosystems, Thermo Fisher, USA). JAK2 rs10974944 polymorphism, which tags the JAK2 46/1 haplotype, was genotyped using a PCR-RFLP assay, as previously described. 16 
| Statistical analysis
The size of the MPL-mutated group (14 ET patients and 5 PMF patients) was deemed too small in order to perform valid statistics.
Thus, we excluded from further analysis this group of patients.
The distribution of qualitative variables was compared between various groups using chi-square statistics, namely Fisher's exact test.
Multivariate logistic regression was used in order to establish the independent influence of each polymorphism. The variables that achieved statistical significance in univariate analysis were included in the regression. In order to test the combined power of the polymorphisms for the diagnosis of MPN, we attempted to create a prediction score. In order to obtain sufficient statistical power, we included the whole cohort of MPN patients in the prediction score. First, we chose the score group, using the covariate adaptive randomization. Individual PAR (Population attributable risk) was calculated for each polymorphism, as previously described. 17 A combined PAR, which takes into account the contribution of all the polymorphisms analyzed was also inferred wherever the case. CI 5 1.1-1.6; P-value 5 .01). In the case of PV, the correlation was reversed, the A allele decreasing the risk of developing this disease, but this was statistically significant only for the homozygous genotype (OR 5 0.5; 95% CI 5 0.3-0.9; P-value 5 .04). When comparing the distribution of rs9376092 between the three diseases, the A allele was seen significantly less frequent in PV than in ET (OR 5 0.6; 95% CI 5 0.5-0.8; P-value 5 .0001).
| RE S U L TS
| THRB-RARB rs4858647
The A allele of rs4858647 was not associated with the global MPN phenotype (OR 5 1.1; 95% CI 5 0.9-1.4; P-value 5 .31). Among the MPN entities, there was a modest correlation between rs4858647 and PMF only (OR 5 1.5; 95% CI 5 1-2.1; P-value 5 .04). The A allele was seen in PV and ET less frequently than in PMF, but these findings did not reach statistical significance (OR 5 0.7; 95% CI 5 0.5-1; P-value 5 .10 and OR 5 0.8; 95% CI 5 0.5-1.1; P-value 5 .14).
| JAK2 46/1 HAPLOTYPE (JAK2 rs10974944)
The G allele of rs10974944 was associated with the global MPN phenotype, (OR 5 2.0; 95% CI 5 0.8-2.4; P-value < .0001), but also with each of the MPN entities (OR 5 2.6; 95% CI 5 2.1-3.1; P-value < .0001 for PV; OR 5 1.6; 95% CI 5 1.3-1.9; P-value < .0001 for ET; OR 5 2.4; 95% CI 5 1.8-3.2; P-value < .0001 for PMF). rs10974944 was significantly overrepresented in PV and PMF compared to ET (OR 5 1.7; 95% CI 5 1.4-2; P-value < .0001 and OR 5 1.5; 95% CI 5 1.2-2; P-value 5 .01, respectively).
| TERT rs2736100
The C allele of rs2736100 was associated with the global MPN phenotype, (OR 5 1.8; 95% CI 5 1.6-2.3; P-value < .0001), and with each of the MPN entities (OR 5 1.8; 95% CI 5 1.5-2.2; P-value < .0001 for PV;
OR 5 1.8; 95% CI 5 1.5-2.2; P-value < .0001 for ET; OR 5 1.9; 95% CI 5 1.4-2.4; P-value < .0001 for PMF). 
| Association of the polymorphisms with MPN:
Multivariate analysis and the prediction score
We found no differences between the subjects from the score group and those from the validation group, regarding the distribution of genotypes for the five polymorphisms analyzed.
The univariate analysis performed on the whole cohort of patients revealed three polymorphisms significantly associated with MPN (the whole cohort of patients): JAK2 rs10974944, TERT rs2736100, and MECOM rs2201862. After performing the multivariate analysis, the following remained statistically significant: the G allele of JAK2 rs10974944 in heterozygous and homozygous state (OR 5 2.2; 95% CI 5 1.7-3; P-value < .0001 and OR 5 2.7; 95% CI 5 1.8-4.2; P-value < .0001, respectively), the C allele of TERT rs2736100 in heterozygous and homozygous state (OR 5 1.9; 95% CI 5 1.3-2.7; Pvalue 5 .0011 and OR 5 3; 95% CI 5 2-4.5; P-value < .0001) and the T allele of MECOM rs2201862 in homozygous state (OR 5 1.9; 95% CI 5 1.3-2.8; P-value 5 .001).
Using the regression coefficients, we calculated a prediction score for MPN. We determined a cut- The T allele of rs2201862 was associated with both JAK2 V617F and CALR-mutated MPN. In the latter case, the effect was considerably 
| HBS1L/MYB rs9376092
The A allele of rs9376092 was not associated with JAK2-mutated or 
| THRB-RARB rs4858647
There was no significant association between rs4858647 and a particular MPN molecular sub-type, neither in the whole MPN cohort, nor in each MPN entity.
| JAK2 46/1 HAPLOTYPE (JAK2 rs10974944)
There was a strong correlation between rs10974944 and JAK2 V617F-mutated MPN (OR 5 2.2; 95% CI 5 1.8-2.6; P-value < .0001).
rs10974944 was also associated with CALR-mutated MPN (OR 5 1. 
| TERT rs2736100
There was a strong correlation between rs2736100 and MPN, regardless of the molecular sub-type (OR 5 1.8; 95% CI 5 1.5-2.1; P-val- 
| Population attributable factors
When taking into account the whole cohort of MPN patients, TERT rs2736100 had the greatest contribution in the risk of developing a MPN, followed by JAK2 rs10974944 and MECOM rs2201862 (PAR 5 54%, 42% and 16%, respectively). These three polymorphisms had a combined PAR of 78%.
The risk of developing PV could be attributed to the same three polymorphisms, but in this case JAK2 rs10974944 had the greatest impact (PAR 5 59%), followed by TERT rs2736100 (PAR 5 51%) and MECOM rs2201862 (22%). The combined analysis of the three polymorphisms revealed a PAR of 84%.
In the case of ET, TERT rs2736100 had the greatest contribution (PAR 5 52%), followed by JAK2 rs10974944 (PAR 5 29%), HBS1L-MYB rs9376092 (PAR 5 12%) and MECOM rs2201862 (PAR 5 11%). The combined PAR of the four polymorphisms was calculated at 74%.
In the case of PMF, TERT rs2736100 and JAK2 rs10974944 polymorphisms had the greatest contribution (PAR 5 68% and 46%, respectively), followed by MECOM rs2201862 (PAR 5 16%), and THRB-RARB rs4858647 (PAR 5 9%). The combined PAR of the four polymorphisms was 87%.
When restricting the analysis to JAK2 V617F-mutated patients,
TERT rs2736100 and JAK2 rs10974944 polymorphisms had the greatest impact (PAR 5 52% and 49%, respectively), followed by MECOM rs2201862 (PAR 5 14%). These three polymorphisms could explain together 79% of JAK2 V617F-mutated MPN patients.
In CALR-mutated patients, TERT rs2736100 had the most important contribution (PAR 5 63%), followed by MECOM rs2201862 (PAR 5 19%), and JAK2 rs10974944 (PAR 5 16%). The combined PAR of the three polymorphisms was 74%. 
| D I SCUSSION S
Our study revealed that JAK2 rs10974944 (which tags the 46/1 haplotype) and TERT rs2736100 polymorphisms had the greatest impact on the risk of developing MPN. Globally, rs10974944 associated especially with JAK2 V617F-mutated MPN. At disease level, it had the strongest contribution to PV and PMF. Interestingly, our data indicate the JAK2 46/1 haplotype predisposes also to CALR-mutated MPN, although to a lesser degree than to JAK2 V617F-mutated MPN. The strong association between the JAK2 46/1 haplotype and JAK2 V617F-mutated MPN would argue against the "hypermutable local milieu" induced by this haplotype. However, a more general consequence at the genomic level cannot be completely ruled out, given its association also with CALR-mutated MPN. In fact, our findings mirror some of the initial works performed on JAK2 46/1 haplotype, that reported it was enriched also in JAK2 V617F-negative MPN, not only in those JAK2 V617F-mutated. 2, 18 It is well known nowadays that most of the JAK2 V617F-negative MPN harbor CALR mutations.
In our study, MECOM rs2201862 had the third strongest influence on the risk of developing MPN. There was a significant global correlation between rs2201862 and MPN. Regarding the MPN phenotypes, it strongly associated with PV, weaker with PMF, while the association with ET bordered the statistical significance. In ET and PMF, rs2201862 associated especially with CALR-mutated disease. Thus, we may conclude that rs2201862 predisposes especially to PV and to CALRmutated ET and PMF, our findings mirroring those reported by Tapper et al. 8 Hinds et al. found a weak support for the association between rs2201862 and MPN, but a stronger evidence for another MECOM polymorphism, namely rs3851379. 9 On the other hand, in the study published by Chiang et al., rs2201862 was not at all associated with ET or PMF, but had a weak effect in decreasing the risk of PV. 19 The MECOM locus, which neighbors rs2201862 polymorphism, has been linked to megakaryopoiesis by several mechanisms, reviewed by Tapper et al. 8 For instance, myeloid malignancies characterized by chromosome rearrangements involving the MECOM locus usually associate elevated platelet count. 8 However, our findings indicate that rs2201862 is associated with all MPN, not only with ET. In fact, our multivariate analysis revealed that TERT rs2736100, JAK2 rs10974944 and MECOM rs2201862 have an independent, statistically significant contribution to the occurrence of MPN. Based on these findings, we were able to create a prediction score for MPN, which takes into account these three polymorphisms. This score has a moderate sensitivity for the prediction of MPN. On the other hand, these three polymorphisms, namely TERT rs2736100, JAK2 rs10974944 and MECOM rs2201862 account for a great proportion of PAR in MPN. TERT rs2736100 has the greatest PAR in all MPN phenotypes and molecular types, but it has the most important contribution to CALR-mutated MPN. TERT rs2736100 and JAK2 rs10974944 had similar PAR in JAK2 V617F-mutated MPN.
In case of HS1L-MYB rs9376092, our findings indicate a positive association between the A allele and ET only. This effect seems to be restricted to JAK2 V617F-mutated disease only. In fact, the magnitude of rs9376092 contribution to ET is similar to that of MECOM Moreover, in ET patients the expression of MYB was lower in JAK2
V617F-positive BFU-E (burst-forming unit-erythroid) colonies compared to those wild-type. 8 On the other hand, MYB knockdown in CD341 human bone marrow cells was previously shown to favor megakaryopoiesis. 20 Thus, polymorphisms near the MYB locus seem to influence its level of expression, a phenomenon facilating the excessive megakaryopoesis specific to ET.
